Literature DB >> 18727664

Cutaneous localized annular chromoblastomycosis.

Claudio G Salgado1, Moises B da Silva, Suellen S P Yamano, Ubirajara I Salgado, José A P Diniz, Jorge P da Silva.   

Abstract

Chromoblastomycosis (CBM) is a difficult-to-treat dermal mycosis characterized by the presence of round, pigmented, sclerotic bodies formed by black fungi found in polymorphic lesions. According to the morphology of a lesion, different clinical types of the disease have been described. We present three patients who each developed a single, 10-cm diameter, 8 to 15-year-old, well-circumscribed, slow-growing, annular, papulosquamous or papulosquamous-verrucous lesion, with no regression despite the use of topical antifungals. Skin scrapings and biopsies confirmed CBM and microculture defined the agent as Fonsecaea pedrosoi. The patients were treated with 200 mg/day of itraconazole for 6-9 months and were discharged after complete regression of the lesions. All were examined after the first and second year of the end of treatment and there were no signs of recurrence. A new clinical type of CBM is described, and itraconazole appears to be effective and safe in curing these patients after no more than 9 months of therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18727664     DOI: 10.1111/j.1600-0560.2008.01025.x

Source DB:  PubMed          Journal:  J Cutan Pathol        ISSN: 0303-6987            Impact factor:   1.587


  6 in total

1.  Fungal x host interactions in Chromoblastomycosis: what we have learned from animal models and what is yet to be solved.

Authors:  Claudio Guedes Salgado
Journal:  Virulence       Date:  2010 Jan-Feb       Impact factor: 5.882

2.  Chromoblastomycosis Caused by Phialophora richardsiae.

Authors:  Young-Min Son; Hong-Kyu Kang; So-Young Na; Hye-Young Lee; Jin-Ok Baek; Jong-Rok Lee; Joo-Young Roh; Yiel-Hea Seo
Journal:  Ann Dermatol       Date:  2010-08-05       Impact factor: 1.444

3.  A case of relapsed chromoblastomycosis due to Fonsecaea monophora: antifungal susceptibility and phylogenetic analysis.

Authors:  Tatiane Caroline Daboit; Cibele Massotti Magagnin; Daiane Heidrich; Mauricio Ramírez Castrillón; Sandra Denise Camargo Mendes; Gerson Vettorato; Patrícia Valente; Maria Lúcia Scroferneker
Journal:  Mycopathologia       Date:  2013-05-04       Impact factor: 2.574

4.  Oral chromoblastomycosis: a case report.

Authors:  M J Fatemi; Fatemi Mj; H Bateni; Bateni H
Journal:  Iran J Microbiol       Date:  2012-03

5.  Molecular Epidemiology of Agents of Human Chromoblastomycosis in Brazil with the Description of Two Novel Species.

Authors:  Renata R Gomes; Vania A Vicente; Conceição M P S de Azevedo; Claudio G Salgado; Moises B da Silva; Flávio Queiroz-Telles; Sirlei G Marques; Daniel W C L Santos; Tania S de Andrade; Elizabeth H Takagi; Katia S Cruz; Gheniffer Fornari; Rosane C Hahn; Maria L Scroferneker; Rachel B Caligine; Mauricio Ramirez-Castrillon; Daniella P de Araújo; Daiane Heidrich; Arnaldo L Colombo; G S de Hoog
Journal:  PLoS Negl Trop Dis       Date:  2016-11-28

Review 6.  Chromoblastomycosis: an etiological, epidemiological, clinical, diagnostic, and treatment update.

Authors:  Arival Cardoso de Brito; Maraya de Jesus Semblano Bittencourt
Journal:  An Bras Dermatol       Date:  2018 Jul-Aug       Impact factor: 1.896

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.